Cytokinetics' SMA candidate improves time to muscle fatigue in Phase II

Cytokinetics Inc. (NASDAQ:CYTK) reported data from ambulatory patients with spinal muscular atrophy (SMA) in a Phase II trial showing that reldesemtiv led to dose-dependent increases in time to

Read the full 282 word article

User Sign In